sarilumab high dose (400mg) for COVID-19 - live meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	RCT OBS RCT + OBS	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID 19 all comers meta-analysis
sarilumab phase 2 high dose unpublished NCT04315298		RCT	sarilumab high dose (400mg)	placebo	COVID 19 all comers	high	145/77	suggested	suggested 61 % decrease in death or ventilation but with a low degree of certainty due to high risk of bias suggested 73 % decrease in ventilation but with a low degree of certainty due to high risk of bias there were negative trends for most outcomes in the “severe” group, while there were positive trends for all outcomes in the “critical” group

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID 19 all comers meta-analysis